Emerging cancer vaccines: Forecasts, new developments and pipeline analysis

Nov 25 2009

The H1N1 vaccine has spurred media interest in vaccines, as well as predictions of vaccines for a host of new diseases. According to Kalorama Information, certain cancers may be added to the list of diseases for which vaccinations will be employed. But this is not a new development. Such vaccines have rather quietly been in development for a decade and an array of products are poised to launch, according to "Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition," from healthcare market research publisher Kalorama Information.

Following the first multi-billion dollar cancer vaccine blockbuster Gardasil, drug makers are taking notice, promising more cancer vaccines on the horizon against the likes of colorectal, lung, breast and prostate cancers. According to Kalorama, cancer vaccine sales will more than double from $1.8 billion in 2008 to $4.2 billion by 2012. This unprecedented growth is creating countless opportunities for market participants.

Past attempts to find cancer vaccines failed because scientists had a crude understanding of the molecular mechanics of the immune system and cancer cells. But patients will soon benefit from advances in DNA profiling and the emerging field of pharmacogenomics. These will lead to tailored treatments based on a tumor's specific genetic profile, allowing physicians to treat tumors based on their genetic make-up rather than their location.

"Several promising vaccines are in late stage development and are preparing for regulatory review in the United States and internationally," notes Kalorama Information analyst Melissa Elder. "Many of the products -- including OncoVAX, TroVAX, and Lucanix -- are already in Phase III development, have orphan drug status, SPA status, or Fast Track status, which promises a bright future for many of these products."

These vaccines will, however, have to overcome a few hurdles, including the reimbursement issue. Manufacturers must not only demonstrate that new vaccines are superior to other products on the market but also that pharmacogenomics and personalized medicine are worth the anticipated additional cost.

Kalorama Information's report "Emerging Cancer Vaccines: Market Forecasts, New Developments and Pipeline Analysis, 3rd Edition," focuses on both preventative and therapeutic cancer vaccines in development. A market overview, cancer statistics, market estimates and forecasts for 2008-2012 are included, as well as discussions of current issues and trends affecting the industry.

SOURCE: Kalorama Information